Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Blinatumomab
Brand Name Blincyto®
Payment Category Medicare Part B
Year Introduced 2014
Type of Drug Bispecific T-cell Engager (BITE®)
Manufacturer Amgen, Onyx Pharmaceuticals
Medical Affairs Questions (date verified) 800.772.6436
Coverage & Reimbursement Questions 855-669-9360
HCPCS J9039
Billing Unit 1 mcg
Medicare Payment Limit (Effective January 1, 2021) $118.12

FDA-Approved Indication(s)

  • Indicated for the treatment of adults and children with 1) B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease greater than or equal to 0.1%, and 2) relapsed or refractory B-cell precursor acute lymphoblastic leukemia. (3/29/18)

Approved Indication(s) with Orphan Drug Status Treatment of acute lymphocytic leukemia
ICD-10 Code(s) for Labeled Indication(s) Acute lymphoblastic leukemia, not having achieved remission [C91.00] or in relapse [C91.02]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US